Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
207 studies found for:    Open Studies | "Leukemia, Myelogenous, Chronic, BCR-ABL Positive"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Leukemia, Myelogenous, Chronic, BCR-ABL Positive"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene
Conditions: Chronic Myeloid Leukemia;   Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Intervention: Drug: PF-114
2 Unknown  Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia in Japan
Conditions: Leukemia, Myelogenous, Chronic, BCR-ABL Positive;   Myelogenous Leukemia, Chronic, Chronic Phase
Intervention:
3 Unknown  Interventional Study to Improve Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Conditions: Leukemia, Myelogenous, Chronic, BCR-ABL Positive;   Medication Adherence
Interventions: Behavioral: Adherence-encouraging interventions - Group meeting;   Behavioral: Adherence-encouraging interventions - Individual meetings;   Behavioral: Adherence-encouraging interventions - Monthly phone calls
4 Not yet recruiting Safety and Efficiency Study of Pioglitazone in Combination With Imatinib Mesylate to Treat Chronic Myelogenous Leukemia
Condition: Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Interventions: Drug: Pioglitazone;   Drug: imatinib mesylate
5 Not yet recruiting National Observatory of Chronic Myeloid Leukemia Adolescent and Young Adults Treated With Tyrosine Kinase Inhibitors in First Intent
Condition: Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Intervention:
6 Not yet recruiting Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia
Conditions: Chronic Myelogenous Leukemia;   Chronic Myeloid Leukemia;   Leukemia
Interventions: Drug: Dasatinib;   Drug: Imatinib Mesylate;   Drug: Nilotinib
7 Recruiting A Study Comparing Ponatinib and Nilotinib in Patients With Chronic Myeloid Leukemia
Condition: Chronic Phase Chronic Myeloid Leukemia
Interventions: Drug: ponatinib 30 mg QD;   Drug: ponatinib 15 mg QD;   Drug: nilotinib 400 mg BID
8 Recruiting Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib
Condition: Chronic Myelogenous Leukemia
Intervention: Drug: Dasatinib
9 Recruiting Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia
Conditions: Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Interventions: Drug: Pioglitazone Hydrochloride;   Drug: Tyrosine Kinase Inhibitor (TKI)
10 Recruiting Regional Central Database Recording of Chronic Myeloid Leukemia
Condition: Chronic Myeloid Leukemia
Intervention: Other: Practices evaluation
11 Not yet recruiting Bosutinib in Elderly Chronic Myeloid Leukemia
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Bosutinib
12 Recruiting Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib
Condition: Chronic Myeloid Leukemia
Intervention: Behavioral: Dasatinib discontinuation
13 Recruiting Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response
Condition: Chronic Phase Chronic Myeloid Leukemia
Intervention: Drug: P1101
14 Recruiting Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Condition: Chronic Myelogenous Leukemia
Intervention: Other: Chart Review
15 Recruiting Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase
Conditions: Chronic Phase Philadelphia Positive;   BCR-ABL Positive;   Chronic Myeloid Leukaemia
Intervention:
16 Recruiting TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy and Tolerability. The TIKlet Study
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Imatinib/Nilotinib
17 Recruiting Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia
Conditions: Chronic Phase Chronic Myeloid Leukemia;   Accelerated Phase Chronic Myeloid Leukemia;   Blastic Phase Chronic Myeloid Leukemia;   Philadelphia Positive Acute Lymphoblastic Leukemia;   Resistant to Tyrosine Kinase Inhibitor Therapy
Interventions: Drug: Nilotinib;   Drug: Ruxolitinib
18 Recruiting LEONIDAS: Quality of Life Study in Chronic Myeloid Leukemia Patients
Condition: Chronic Myeloid Leukemia
Intervention: Other: QoL Survey Booklet
19 Not yet recruiting Bosutinib Dose-Optimization Study in Chronic Myeloid Leukemia (CML)
Condition: Chronic Myelogenous Leukemia
Interventions: Drug: Bosutinib;   Behavioral: Phone Calls;   Behavioral: Questionnaires
20 Recruiting Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors.
Condition: Philidelphia Positive Chronic Myeloid Leukaemia
Intervention: Drug: Nilotinib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years